{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T01:31:31Z","timestamp":1656811891234},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2000,6,1]],"date-time":"2000-06-01T00:00:00Z","timestamp":959817600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2000,6]]},"DOI":"10.1208\/pt010208","type":"journal-article","created":{"date-parts":[[2004,4,9]],"date-time":"2004-04-09T17:11:21Z","timestamp":1081530681000},"page":"8-13","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pramlintide injection drug product robustness studies"],"prefix":"10.1208","volume":"1","author":[{"given":"Richard A.","family":"Kenley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Bancroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"L'Italien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Stepanenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trupti","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,19]]},"reference":[{"key":"128_CR1","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1042\/bst0230325","volume":"23","author":"A Young","year":"1995","unstructured":"Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin Regulation of carbohydrate metabolism. Biochem Soc Trans. 1995;23:325\u2013331.","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"128_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0029-1211958","volume":"106","author":"WA Scherbaum","year":"1998","unstructured":"Scherbaum WA. The role of amylin in the physiology of glycemic control. Experimental and Clinical Endocrinol and Diabetes. 1998:106(2):97\u2013102.","journal-title":"Experimental and Clinical Endocrinol and Diabetes"},{"key":"128_CR3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0140-6736(93)91153-D","volume":"341","author":"S Amiel","year":"1993","unstructured":"Amiel S. Amylin and diabetes. Lancet. 1993:341:1249\u20131250.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"128_CR4","first-page":"235A","volume":"45","author":"S Janes","year":"1996","unstructured":"Janes S, Gaeta L, Beaumont K, Beeley K, Rink T. The selection of pramlintide for clinical evaluation. Diabetes. 1996;45 (Suppl 2): 235A.","journal-title":"Diabetes"},{"issue":"7","key":"128_CR5","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U","volume":"14","author":"RG Thompson","year":"1997","unstructured":"Thompson RG, Gottlieb A, Organ K, Kolterman OG. Pramlintide, a human amylin analog reduced post-prandial plasma glucose, insulin and epeptide concentrations in patients with type II diabetes. Diabetic Medicine. 1997;14(7):547\u2013555.","journal-title":"Diabetic Medicine"},{"issue":"4","key":"128_CR6","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/diabetes.46.4.632","volume":"46","author":"RG Thompson","year":"1997","unstructured":"Thompson RG, Peterson J, Gottlieb A, Mullane J. Effects of pramlintide, an analog of human amylin on plasma glucose profiles in patients with IDDM: results of a multi-center trial. Diabetes. 1997;46(4):632\u2013636.","journal-title":"Diabetes"},{"issue":"10","key":"128_CR7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nbt1097-935","volume":"15","author":"V Brower","year":"1997","unstructured":"Brower V. Amylin's pramlintide best of bad bunch of diabetes drugs. Nature Biotechnol. 1997;15(10):935.","journal-title":"Nature Biotechnol"},{"key":"128_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1023\/A:1011934829263","volume":"15","author":"C Hekman","year":"1998","unstructured":"Hekman C, Demond W, Dixit T, et al. Isolation and identification of peptide degradation products of heat stressed pramlintide injection. Pharmaceutical Research 1998;15:650\u2013659.","journal-title":"Pharmaceutical Research"},{"key":"128_CR9","doi-asserted-by":"crossref","unstructured":"Kenley R, Demond W, L'Italien J, Lokensgard D, Weilersbacher G. Orthogonal HPLC methods for quantitating related substances and degradation products of pramlintide.AAPS PharmSciTech 1(n1) 2000 (http:\/\/www.pharmscitech.com|url)","DOI":"10.1007\/BF02830521"},{"key":"128_CR10","doi-asserted-by":"crossref","unstructured":"Kenley R, Tracht S, Stepanenko A, Townsend M, L'Italien J. Kinetics of pramlintide degradation in aqueous solution as a function of temperature and p..AAPS PharmSciTech 1(2) 2000 (http:\/\/www.pharmscitech.com|url)","DOI":"10.1007\/BF02830522"},{"key":"128_CR11","unstructured":"International Committee on Harmonization ICH Q5C. \u201cGuideline for Industry: Quality of Biotechnological Products: Stability Testing of Biotechnological\/Biological Products\u201d. Section VI.C.1996."},{"key":"128_CR12","unstructured":"Committee for Proprietary Medicinal Products. European Agency for the Evaluation of Medicinal Products. \u201cNote for Guidance on Inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products\u201d. Section 8. 1998."},{"key":"128_CR13","unstructured":"Committee for Proprietary Medicinal Products. European Agency for the Evaluation of Medicinal Products. \u201cNote for Guidance on Development Pharmaceutics\u201d. Section 3.3.1., 1998."},{"key":"128_CR14","unstructured":"U.S. Food and Drug Administration Center for Drug Evaluation and Research, Department of Health and Human Services. \u201cGuideline for Submitting Documentation for Packaging for Human Drugs and Biologics\u201d. Section III.B. 1987."},{"key":"128_CR15","unstructured":"International Committee on Hamonization ICH Q5C \u201cGuideline for Industry: Quality of Biotechnological Products: Stability Testing of Biotechnological Biological Products\u201d. Section VI.E. 1996."}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/pt010208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/pt010208\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/pt010208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T03:41:59Z","timestamp":1559619719000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/pt010208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,6]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2000,6]]}},"alternative-id":["128"],"URL":"https:\/\/doi.org\/10.1208\/pt010208","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,6]]}}}